nodes	percent_of_prediction	percent_of_DWPC	metapath
Albendazole—ABCB1—Methylprednisolone—multiple sclerosis	0.0793	0.11	CbGbCtD
Albendazole—CYP1A1—Dexamethasone—multiple sclerosis	0.0768	0.107	CbGbCtD
Albendazole—CYP3A4—Fingolimod—multiple sclerosis	0.0737	0.103	CbGbCtD
Albendazole—ABCB1—Mitoxantrone—multiple sclerosis	0.0578	0.0805	CbGbCtD
Albendazole—ABCB1—Betamethasone—multiple sclerosis	0.0516	0.0718	CbGbCtD
Albendazole—ABCB1—Prednisolone—multiple sclerosis	0.0509	0.0708	CbGbCtD
Albendazole—ABCB1—Prednisone—multiple sclerosis	0.048	0.0669	CbGbCtD
Albendazole—CYP3A4—Methylprednisolone—multiple sclerosis	0.0475	0.0661	CbGbCtD
Albendazole—CYP3A4—Triamcinolone—multiple sclerosis	0.036	0.0501	CbGbCtD
Albendazole—CYP3A4—Mitoxantrone—multiple sclerosis	0.0347	0.0482	CbGbCtD
Albendazole—CYP3A4—Betamethasone—multiple sclerosis	0.0309	0.043	CbGbCtD
Albendazole—CYP3A4—Prednisolone—multiple sclerosis	0.0305	0.0424	CbGbCtD
Albendazole—ABCB1—Dexamethasone—multiple sclerosis	0.03	0.0417	CbGbCtD
Albendazole—CYP3A4—Prednisone—multiple sclerosis	0.0288	0.0401	CbGbCtD
Albendazole—ABCB1—Methotrexate—multiple sclerosis	0.0241	0.0335	CbGbCtD
Albendazole—TUBA1A—pons—multiple sclerosis	0.0228	0.188	CbGeAlD
Albendazole—CYP3A4—Dexamethasone—multiple sclerosis	0.018	0.025	CbGbCtD
Albendazole—TUBA1A—pineal body—multiple sclerosis	0.0163	0.134	CbGeAlD
Albendazole—TUBA1A—peripheral nervous system—multiple sclerosis	0.0152	0.125	CbGeAlD
Albendazole—TUBA1A—nerve—multiple sclerosis	0.0118	0.0977	CbGeAlD
Albendazole—TUBA1A—brainstem—multiple sclerosis	0.00509	0.0419	CbGeAlD
Albendazole—TUBA1A—retina—multiple sclerosis	0.00491	0.0405	CbGeAlD
Albendazole—TUBA1A—Azacitidine—Cladribine—multiple sclerosis	0.00482	1	CbGdCrCtD
Albendazole—Intracranial pressure increased—Prednisolone—multiple sclerosis	0.0042	0.0274	CcSEcCtD
Albendazole—Intracranial pressure increased—Triamcinolone—multiple sclerosis	0.00386	0.0252	CcSEcCtD
Albendazole—Intracranial pressure increased—Methylprednisolone—multiple sclerosis	0.00385	0.0252	CcSEcCtD
Albendazole—Liver function test abnormal—Fingolimod—multiple sclerosis	0.00385	0.0251	CcSEcCtD
Albendazole—TUBA1A—medulla oblongata—multiple sclerosis	0.00355	0.0292	CbGeAlD
Albendazole—Intracranial pressure increased—Dexamethasone—multiple sclerosis	0.0035	0.0229	CcSEcCtD
Albendazole—Intracranial pressure increased—Betamethasone—multiple sclerosis	0.0035	0.0229	CcSEcCtD
Albendazole—TUBB4B—retina—multiple sclerosis	0.00327	0.027	CbGeAlD
Albendazole—TUBA1A—midbrain—multiple sclerosis	0.00324	0.0267	CbGeAlD
Albendazole—TUBA1A—spinal cord—multiple sclerosis	0.00316	0.0261	CbGeAlD
Albendazole—Aplastic anaemia—Cladribine—multiple sclerosis	0.00305	0.02	CcSEcCtD
Albendazole—Intracranial pressure increased—Prednisone—multiple sclerosis	0.00305	0.0199	CcSEcCtD
Albendazole—TUBA1A—nervous system—multiple sclerosis	0.00266	0.022	CbGeAlD
Albendazole—TUBA1A—central nervous system—multiple sclerosis	0.00256	0.0212	CbGeAlD
Albendazole—Renal failure acute—Cladribine—multiple sclerosis	0.00256	0.0167	CcSEcCtD
Albendazole—Alopecia—Fingolimod—multiple sclerosis	0.00255	0.0166	CcSEcCtD
Albendazole—TUBA1A—cerebellum—multiple sclerosis	0.00251	0.0207	CbGeAlD
Albendazole—Aplastic anaemia—Azathioprine—multiple sclerosis	0.00248	0.0162	CcSEcCtD
Albendazole—TUBB4B—medulla oblongata—multiple sclerosis	0.00236	0.0195	CbGeAlD
Albendazole—Leukopenia—Fingolimod—multiple sclerosis	0.00225	0.0147	CcSEcCtD
Albendazole—TUBB4B—midbrain—multiple sclerosis	0.00216	0.0178	CbGeAlD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00212	0.0139	CcSEcCtD
Albendazole—TUBB4B—spinal cord—multiple sclerosis	0.00211	0.0174	CbGeAlD
Albendazole—TUBA1A—brain—multiple sclerosis	0.00204	0.0168	CbGeAlD
Albendazole—Skin disorder—Fingolimod—multiple sclerosis	0.00199	0.013	CcSEcCtD
Albendazole—Pancytopenia—Cladribine—multiple sclerosis	0.00194	0.0127	CcSEcCtD
Albendazole—Neutropenia—Cladribine—multiple sclerosis	0.00191	0.0125	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Cladribine—multiple sclerosis	0.0018	0.0118	CcSEcCtD
Albendazole—TUBB4B—nervous system—multiple sclerosis	0.00178	0.0146	CbGeAlD
Albendazole—Hepatobiliary disease—Cladribine—multiple sclerosis	0.00172	0.0112	CcSEcCtD
Albendazole—TUBB4B—central nervous system—multiple sclerosis	0.00171	0.0141	CbGeAlD
Albendazole—Renal failure acute—Mitoxantrone—multiple sclerosis	0.00168	0.011	CcSEcCtD
Albendazole—TUBB4B—cerebellum—multiple sclerosis	0.00167	0.0138	CbGeAlD
Albendazole—Urinary tract disorder—Cladribine—multiple sclerosis	0.00161	0.0105	CcSEcCtD
Albendazole—Urethral disorder—Cladribine—multiple sclerosis	0.0016	0.0105	CcSEcCtD
Albendazole—Pancytopenia—Azathioprine—multiple sclerosis	0.00158	0.0103	CcSEcCtD
Albendazole—Erythema multiforme—Cladribine—multiple sclerosis	0.00154	0.0101	CcSEcCtD
Albendazole—Immune system disorder—Cladribine—multiple sclerosis	0.00148	0.00964	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Azathioprine—multiple sclerosis	0.00147	0.00958	CcSEcCtD
Albendazole—Alopecia—Cladribine—multiple sclerosis	0.00144	0.00943	CcSEcCtD
Albendazole—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.0014	0.00914	CcSEcCtD
Albendazole—Agranulocytosis—Azathioprine—multiple sclerosis	0.00138	0.00902	CcSEcCtD
Albendazole—TUBB4B—brain—multiple sclerosis	0.00136	0.0112	CbGeAlD
Albendazole—Dizziness—Fingolimod—multiple sclerosis	0.00135	0.00885	CcSEcCtD
Albendazole—Headache—Fingolimod—multiple sclerosis	0.00128	0.00838	CcSEcCtD
Albendazole—Pancytopenia—Mitoxantrone—multiple sclerosis	0.00127	0.00832	CcSEcCtD
Albendazole—Erythema multiforme—Azathioprine—multiple sclerosis	0.00126	0.0082	CcSEcCtD
Albendazole—Neutropenia—Mitoxantrone—multiple sclerosis	0.00125	0.0082	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.0012	0.00785	CcSEcCtD
Albendazole—Immune system disorder—Azathioprine—multiple sclerosis	0.0012	0.00784	CcSEcCtD
Albendazole—Alopecia—Azathioprine—multiple sclerosis	0.00117	0.00767	CcSEcCtD
Albendazole—Thrombocytopenia—Cladribine—multiple sclerosis	0.00114	0.00742	CcSEcCtD
Albendazole—Skin disorder—Cladribine—multiple sclerosis	0.00113	0.00736	CcSEcCtD
Albendazole—Agranulocytosis—Mitoxantrone—multiple sclerosis	0.00112	0.00729	CcSEcCtD
Albendazole—Hepatitis—Mitoxantrone—multiple sclerosis	0.00107	0.00702	CcSEcCtD
Albendazole—Leukopenia—Azathioprine—multiple sclerosis	0.00104	0.00676	CcSEcCtD
Albendazole—Aplastic anaemia—Methotrexate—multiple sclerosis	0.001	0.00653	CcSEcCtD
Albendazole—CYP1A1—nervous system—multiple sclerosis	0.000994	0.0082	CbGeAlD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000978	0.00639	CcSEcCtD
Albendazole—CYP1A1—central nervous system—multiple sclerosis	0.000957	0.0079	CbGeAlD
Albendazole—ABCB1—retina—multiple sclerosis	0.000951	0.00784	CbGeAlD
Albendazole—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000949	0.0062	CcSEcCtD
Albendazole—Alopecia—Mitoxantrone—multiple sclerosis	0.000949	0.0062	CcSEcCtD
Albendazole—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000924	0.00604	CcSEcCtD
Albendazole—Urticaria—Cladribine—multiple sclerosis	0.000922	0.00602	CcSEcCtD
Albendazole—Abdominal pain—Cladribine—multiple sclerosis	0.000917	0.00599	CcSEcCtD
Albendazole—Body temperature increased—Cladribine—multiple sclerosis	0.000917	0.00599	CcSEcCtD
Albendazole—Skin disorder—Azathioprine—multiple sclerosis	0.000917	0.00599	CcSEcCtD
Albendazole—Hypersensitivity—Cladribine—multiple sclerosis	0.000855	0.00559	CcSEcCtD
Albendazole—Renal failure acute—Methotrexate—multiple sclerosis	0.000838	0.00547	CcSEcCtD
Albendazole—Leukopenia—Mitoxantrone—multiple sclerosis	0.000837	0.00547	CcSEcCtD
Albendazole—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000772	0.00504	CcSEcCtD
Albendazole—Dizziness—Cladribine—multiple sclerosis	0.000767	0.00501	CcSEcCtD
Albendazole—CYP1A1—brain—multiple sclerosis	0.00076	0.00627	CbGeAlD
Albendazole—Neutropenia—Prednisone—multiple sclerosis	0.000748	0.00489	CcSEcCtD
Albendazole—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000747	0.00488	CcSEcCtD
Albendazole—Body temperature increased—Azathioprine—multiple sclerosis	0.000746	0.00487	CcSEcCtD
Albendazole—Abdominal pain—Azathioprine—multiple sclerosis	0.000746	0.00487	CcSEcCtD
Albendazole—Skin disorder—Mitoxantrone—multiple sclerosis	0.000741	0.00484	CcSEcCtD
Albendazole—Vomiting—Cladribine—multiple sclerosis	0.000738	0.00482	CcSEcCtD
Albendazole—Rash—Cladribine—multiple sclerosis	0.000732	0.00478	CcSEcCtD
Albendazole—Dermatitis—Cladribine—multiple sclerosis	0.000731	0.00478	CcSEcCtD
Albendazole—Immune system disorder—Methylprednisolone—multiple sclerosis	0.00073	0.00477	CcSEcCtD
Albendazole—CYP3A4—nervous system—multiple sclerosis	0.00073	0.00602	CbGeAlD
Albendazole—Headache—Cladribine—multiple sclerosis	0.000727	0.00475	CcSEcCtD
Albendazole—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000714	0.00466	CcSEcCtD
Albendazole—CYP3A4—central nervous system—multiple sclerosis	0.000702	0.00579	CbGeAlD
Albendazole—Hypersensitivity—Azathioprine—multiple sclerosis	0.000695	0.00454	CcSEcCtD
Albendazole—Nausea—Cladribine—multiple sclerosis	0.000689	0.0045	CcSEcCtD
Albendazole—Vertigo—Prednisolone—multiple sclerosis	0.000689	0.0045	CcSEcCtD
Albendazole—ABCB1—medulla oblongata—multiple sclerosis	0.000687	0.00567	CbGeAlD
Albendazole—Alopecia—Dexamethasone—multiple sclerosis	0.00065	0.00424	CcSEcCtD
Albendazole—Alopecia—Betamethasone—multiple sclerosis	0.00065	0.00424	CcSEcCtD
Albendazole—Pancytopenia—Methotrexate—multiple sclerosis	0.000635	0.00415	CcSEcCtD
Albendazole—Vertigo—Triamcinolone—multiple sclerosis	0.000634	0.00414	CcSEcCtD
Albendazole—Vertigo—Methylprednisolone—multiple sclerosis	0.000632	0.00413	CcSEcCtD
Albendazole—ABCB1—midbrain—multiple sclerosis	0.000628	0.00518	CbGeAlD
Albendazole—Neutropenia—Methotrexate—multiple sclerosis	0.000625	0.00408	CcSEcCtD
Albendazole—Dizziness—Azathioprine—multiple sclerosis	0.000624	0.00408	CcSEcCtD
Albendazole—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000624	0.00408	CcSEcCtD
Albendazole—ABCB1—spinal cord—multiple sclerosis	0.000613	0.00506	CbGeAlD
Albendazole—Urticaria—Mitoxantrone—multiple sclerosis	0.000606	0.00396	CcSEcCtD
Albendazole—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000603	0.00394	CcSEcCtD
Albendazole—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000603	0.00394	CcSEcCtD
Albendazole—Vomiting—Azathioprine—multiple sclerosis	0.0006	0.00392	CcSEcCtD
Albendazole—Rash—Azathioprine—multiple sclerosis	0.000595	0.00389	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000595	0.00389	CcSEcCtD
Albendazole—Dermatitis—Azathioprine—multiple sclerosis	0.000594	0.00388	CcSEcCtD
Albendazole—Headache—Azathioprine—multiple sclerosis	0.000591	0.00386	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000591	0.00386	CcSEcCtD
Albendazole—Immune system disorder—Prednisone—multiple sclerosis	0.000578	0.00378	CcSEcCtD
Albendazole—Vertigo—Betamethasone—multiple sclerosis	0.000575	0.00376	CcSEcCtD
Albendazole—Vertigo—Dexamethasone—multiple sclerosis	0.000575	0.00376	CcSEcCtD
Albendazole—Alopecia—Prednisone—multiple sclerosis	0.000566	0.0037	CcSEcCtD
Albendazole—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000564	0.00368	CcSEcCtD
Albendazole—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000562	0.00367	CcSEcCtD
Albendazole—Nausea—Azathioprine—multiple sclerosis	0.000561	0.00366	CcSEcCtD
Albendazole—Skin disorder—Methylprednisolone—multiple sclerosis	0.000558	0.00364	CcSEcCtD
Albendazole—Agranulocytosis—Methotrexate—multiple sclerosis	0.000556	0.00363	CcSEcCtD
Albendazole—Hepatitis—Methotrexate—multiple sclerosis	0.000535	0.0035	CcSEcCtD
Albendazole—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000528	0.00345	CcSEcCtD
Albendazole—Urethral disorder—Methotrexate—multiple sclerosis	0.000524	0.00343	CcSEcCtD
Albendazole—ABCB1—nervous system—multiple sclerosis	0.000516	0.00426	CbGeAlD
Albendazole—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000511	0.00334	CcSEcCtD
Albendazole—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000511	0.00334	CcSEcCtD
Albendazole—Erythema multiforme—Methotrexate—multiple sclerosis	0.000506	0.0033	CcSEcCtD
Albendazole—Vertigo—Prednisone—multiple sclerosis	0.000501	0.00327	CcSEcCtD
Albendazole—ABCB1—central nervous system—multiple sclerosis	0.000497	0.0041	CbGeAlD
Albendazole—Urticaria—Prednisolone—multiple sclerosis	0.000497	0.00325	CcSEcCtD
Albendazole—ABCB1—cerebellum—multiple sclerosis	0.000486	0.00401	CbGeAlD
Albendazole—Vomiting—Mitoxantrone—multiple sclerosis	0.000485	0.00317	CcSEcCtD
Albendazole—Immune system disorder—Methotrexate—multiple sclerosis	0.000483	0.00316	CcSEcCtD
Albendazole—Rash—Mitoxantrone—multiple sclerosis	0.000481	0.00314	CcSEcCtD
Albendazole—Dermatitis—Mitoxantrone—multiple sclerosis	0.000481	0.00314	CcSEcCtD
Albendazole—Headache—Mitoxantrone—multiple sclerosis	0.000478	0.00312	CcSEcCtD
Albendazole—Alopecia—Methotrexate—multiple sclerosis	0.000473	0.00309	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000471	0.00308	CcSEcCtD
Albendazole—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00047	0.00307	CcSEcCtD
Albendazole—Hypersensitivity—Prednisolone—multiple sclerosis	0.000461	0.00301	CcSEcCtD
Albendazole—Urticaria—Triamcinolone—multiple sclerosis	0.000457	0.00299	CcSEcCtD
Albendazole—Urticaria—Methylprednisolone—multiple sclerosis	0.000456	0.00298	CcSEcCtD
Albendazole—Body temperature increased—Triamcinolone—multiple sclerosis	0.000455	0.00297	CcSEcCtD
Albendazole—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000454	0.00297	CcSEcCtD
Albendazole—Nausea—Mitoxantrone—multiple sclerosis	0.000453	0.00296	CcSEcCtD
Albendazole—Skin disorder—Prednisone—multiple sclerosis	0.000442	0.00289	CcSEcCtD
Albendazole—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000427	0.00279	CcSEcCtD
Albendazole—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000427	0.00279	CcSEcCtD
Albendazole—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000424	0.00277	CcSEcCtD
Albendazole—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000423	0.00276	CcSEcCtD
Albendazole—Vertigo—Methotrexate—multiple sclerosis	0.000418	0.00273	CcSEcCtD
Albendazole—Leukopenia—Methotrexate—multiple sclerosis	0.000417	0.00272	CcSEcCtD
Albendazole—Urticaria—Dexamethasone—multiple sclerosis	0.000415	0.00271	CcSEcCtD
Albendazole—Urticaria—Betamethasone—multiple sclerosis	0.000415	0.00271	CcSEcCtD
Albendazole—Dizziness—Prednisolone—multiple sclerosis	0.000414	0.0027	CcSEcCtD
Albendazole—Abdominal pain—Dexamethasone—multiple sclerosis	0.000413	0.0027	CcSEcCtD
Albendazole—Abdominal pain—Betamethasone—multiple sclerosis	0.000413	0.0027	CcSEcCtD
Albendazole—Body temperature increased—Dexamethasone—multiple sclerosis	0.000413	0.0027	CcSEcCtD
Albendazole—Body temperature increased—Betamethasone—multiple sclerosis	0.000413	0.0027	CcSEcCtD
Albendazole—ABCB1—brain—multiple sclerosis	0.000395	0.00326	CbGeAlD
Albendazole—Rash—Prednisolone—multiple sclerosis	0.000395	0.00258	CcSEcCtD
Albendazole—Dermatitis—Prednisolone—multiple sclerosis	0.000394	0.00258	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000394	0.00257	CcSEcCtD
Albendazole—Headache—Prednisolone—multiple sclerosis	0.000392	0.00256	CcSEcCtD
Albendazole—Dizziness—Triamcinolone—multiple sclerosis	0.000381	0.00249	CcSEcCtD
Albendazole—Dizziness—Methylprednisolone—multiple sclerosis	0.00038	0.00248	CcSEcCtD
Albendazole—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000372	0.00243	CcSEcCtD
Albendazole—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000372	0.00243	CcSEcCtD
Albendazole—Nausea—Prednisolone—multiple sclerosis	0.000372	0.00243	CcSEcCtD
Albendazole—Skin disorder—Methotrexate—multiple sclerosis	0.000369	0.00241	CcSEcCtD
Albendazole—Vomiting—Triamcinolone—multiple sclerosis	0.000366	0.00239	CcSEcCtD
Albendazole—Vomiting—Methylprednisolone—multiple sclerosis	0.000365	0.00239	CcSEcCtD
Albendazole—Rash—Triamcinolone—multiple sclerosis	0.000363	0.00237	CcSEcCtD
Albendazole—Dermatitis—Triamcinolone—multiple sclerosis	0.000363	0.00237	CcSEcCtD
Albendazole—Rash—Methylprednisolone—multiple sclerosis	0.000362	0.00237	CcSEcCtD
Albendazole—Dermatitis—Methylprednisolone—multiple sclerosis	0.000362	0.00236	CcSEcCtD
Albendazole—Urticaria—Prednisone—multiple sclerosis	0.000361	0.00236	CcSEcCtD
Albendazole—Headache—Triamcinolone—multiple sclerosis	0.000361	0.00236	CcSEcCtD
Albendazole—Headache—Methylprednisolone—multiple sclerosis	0.00036	0.00235	CcSEcCtD
Albendazole—Body temperature increased—Prednisone—multiple sclerosis	0.00036	0.00235	CcSEcCtD
Albendazole—Abdominal pain—Prednisone—multiple sclerosis	0.00036	0.00235	CcSEcCtD
Albendazole—Dizziness—Betamethasone—multiple sclerosis	0.000345	0.00226	CcSEcCtD
Albendazole—Dizziness—Dexamethasone—multiple sclerosis	0.000345	0.00226	CcSEcCtD
Albendazole—Nausea—Triamcinolone—multiple sclerosis	0.000342	0.00223	CcSEcCtD
Albendazole—Nausea—Methylprednisolone—multiple sclerosis	0.000341	0.00223	CcSEcCtD
Albendazole—Hypersensitivity—Prednisone—multiple sclerosis	0.000335	0.00219	CcSEcCtD
Albendazole—Vomiting—Dexamethasone—multiple sclerosis	0.000332	0.00217	CcSEcCtD
Albendazole—Vomiting—Betamethasone—multiple sclerosis	0.000332	0.00217	CcSEcCtD
Albendazole—Rash—Betamethasone—multiple sclerosis	0.000329	0.00215	CcSEcCtD
Albendazole—Rash—Dexamethasone—multiple sclerosis	0.000329	0.00215	CcSEcCtD
Albendazole—Dermatitis—Dexamethasone—multiple sclerosis	0.000329	0.00215	CcSEcCtD
Albendazole—Dermatitis—Betamethasone—multiple sclerosis	0.000329	0.00215	CcSEcCtD
Albendazole—Headache—Dexamethasone—multiple sclerosis	0.000327	0.00214	CcSEcCtD
Albendazole—Headache—Betamethasone—multiple sclerosis	0.000327	0.00214	CcSEcCtD
Albendazole—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000311	0.00203	CcSEcCtD
Albendazole—Nausea—Betamethasone—multiple sclerosis	0.00031	0.00203	CcSEcCtD
Albendazole—Nausea—Dexamethasone—multiple sclerosis	0.00031	0.00203	CcSEcCtD
Albendazole—Urticaria—Methotrexate—multiple sclerosis	0.000302	0.00197	CcSEcCtD
Albendazole—Dizziness—Prednisone—multiple sclerosis	0.000301	0.00196	CcSEcCtD
Albendazole—Abdominal pain—Methotrexate—multiple sclerosis	0.0003	0.00196	CcSEcCtD
Albendazole—Body temperature increased—Methotrexate—multiple sclerosis	0.0003	0.00196	CcSEcCtD
Albendazole—Vomiting—Prednisone—multiple sclerosis	0.000289	0.00189	CcSEcCtD
Albendazole—Rash—Prednisone—multiple sclerosis	0.000287	0.00187	CcSEcCtD
Albendazole—Dermatitis—Prednisone—multiple sclerosis	0.000286	0.00187	CcSEcCtD
Albendazole—Headache—Prednisone—multiple sclerosis	0.000285	0.00186	CcSEcCtD
Albendazole—Hypersensitivity—Methotrexate—multiple sclerosis	0.00028	0.00183	CcSEcCtD
Albendazole—Nausea—Prednisone—multiple sclerosis	0.00027	0.00176	CcSEcCtD
Albendazole—Dizziness—Methotrexate—multiple sclerosis	0.000251	0.00164	CcSEcCtD
Albendazole—Vomiting—Methotrexate—multiple sclerosis	0.000242	0.00158	CcSEcCtD
Albendazole—Rash—Methotrexate—multiple sclerosis	0.00024	0.00157	CcSEcCtD
Albendazole—Dermatitis—Methotrexate—multiple sclerosis	0.000239	0.00156	CcSEcCtD
Albendazole—Headache—Methotrexate—multiple sclerosis	0.000238	0.00156	CcSEcCtD
Albendazole—Nausea—Methotrexate—multiple sclerosis	0.000226	0.00147	CcSEcCtD
Albendazole—TUBA1A—p73 transcription factor network—IL4R—multiple sclerosis	0.000127	0.0533	CbGpPWpGaD
Albendazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	5.6e-05	0.0236	CbGpPWpGaD
Albendazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	5.6e-05	0.0236	CbGpPWpGaD
Albendazole—TUBA1A—Pathogenic Escherichia coli infection—TLR4—multiple sclerosis	5.32e-05	0.0224	CbGpPWpGaD
Albendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	4.47e-05	0.0188	CbGpPWpGaD
Albendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	4.47e-05	0.0188	CbGpPWpGaD
Albendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	4.45e-05	0.0187	CbGpPWpGaD
Albendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	4.45e-05	0.0187	CbGpPWpGaD
Albendazole—TUBA1A—p73 transcription factor network—FAS—multiple sclerosis	4.43e-05	0.0187	CbGpPWpGaD
Albendazole—CYP1A1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	4.39e-05	0.0185	CbGpPWpGaD
Albendazole—CYP1A1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	4.39e-05	0.0185	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	3.81e-05	0.0161	CbGpPWpGaD
Albendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	3.61e-05	0.0152	CbGpPWpGaD
Albendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	3.61e-05	0.0152	CbGpPWpGaD
Albendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	3.45e-05	0.0145	CbGpPWpGaD
Albendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	3.45e-05	0.0145	CbGpPWpGaD
Albendazole—TUBB4B—Pathogenic Escherichia coli infection—TLR4—multiple sclerosis	3.22e-05	0.0135	CbGpPWpGaD
Albendazole—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	3.19e-05	0.0134	CbGpPWpGaD
Albendazole—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	3.05e-05	0.0129	CbGpPWpGaD
Albendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	2.84e-05	0.0119	CbGpPWpGaD
Albendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	2.84e-05	0.0119	CbGpPWpGaD
Albendazole—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	2.8e-05	0.0118	CbGpPWpGaD
Albendazole—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	2.8e-05	0.0118	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	2.43e-05	0.0102	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—C4A—multiple sclerosis	2.42e-05	0.0102	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	2.39e-05	0.0101	CbGpPWpGaD
Albendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	2.3e-05	0.00968	CbGpPWpGaD
Albendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	2.3e-05	0.00968	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—SLC30A7—multiple sclerosis	2.26e-05	0.0095	CbGpPWpGaD
Albendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	2.19e-05	0.00922	CbGpPWpGaD
Albendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	2.19e-05	0.00922	CbGpPWpGaD
Albendazole—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	2.16e-05	0.0091	CbGpPWpGaD
Albendazole—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	2.16e-05	0.0091	CbGpPWpGaD
Albendazole—CYP1A1—Estrogen Receptor Pathway—STAT3—multiple sclerosis	2.12e-05	0.00891	CbGpPWpGaD
Albendazole—CYP1A1—Melatonin metabolism and effects—APOE—multiple sclerosis	2.08e-05	0.00877	CbGpPWpGaD
Albendazole—TUBA1A—p73 transcription factor network—MYC—multiple sclerosis	2.02e-05	0.00851	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.98e-05	0.00833	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	1.98e-05	0.00832	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	1.98e-05	0.00832	CbGpPWpGaD
Albendazole—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	1.96e-05	0.00827	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—CYP27B1—multiple sclerosis	1.92e-05	0.00807	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—CYP24A1—multiple sclerosis	1.92e-05	0.00807	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.89e-05	0.00795	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.89e-05	0.00795	CbGpPWpGaD
Albendazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	1.83e-05	0.00771	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—PABPC1—multiple sclerosis	1.82e-05	0.00768	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	1.8e-05	0.00757	CbGpPWpGaD
Albendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	1.77e-05	0.00747	CbGpPWpGaD
Albendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	1.77e-05	0.00747	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	1.7e-05	0.00714	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—RPL5—multiple sclerosis	1.65e-05	0.00693	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	1.54e-05	0.00648	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	1.53e-05	0.00643	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	1.5e-05	0.00631	CbGpPWpGaD
Albendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	1.46e-05	0.00615	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—SLC30A7—multiple sclerosis	1.36e-05	0.00573	CbGpPWpGaD
Albendazole—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	1.35e-05	0.00568	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	1.33e-05	0.00562	CbGpPWpGaD
Albendazole—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	1.33e-05	0.00559	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CD28—multiple sclerosis	1.3e-05	0.00546	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	1.24e-05	0.00523	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	1.23e-05	0.00518	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	1.22e-05	0.00514	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	1.22e-05	0.00514	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.2e-05	0.00507	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.2e-05	0.00507	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—BCHE—multiple sclerosis	1.2e-05	0.00507	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—AQP4—multiple sclerosis	1.18e-05	0.00499	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CD40—multiple sclerosis	1.18e-05	0.00498	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	1.17e-05	0.00491	CbGpPWpGaD
Albendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	1.13e-05	0.00475	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—PABPC1—multiple sclerosis	1.1e-05	0.00464	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	1.07e-05	0.00449	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.05e-05	0.00441	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	1.03e-05	0.00434	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	1.03e-05	0.00433	CbGpPWpGaD
Albendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1e-05	0.00421	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—RPL5—multiple sclerosis	9.93e-06	0.00418	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	9.61e-06	0.00405	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	9.43e-06	0.00397	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	9.43e-06	0.00397	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	9.3e-06	0.00391	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	9.3e-06	0.00391	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CD86—multiple sclerosis	9.25e-06	0.0039	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	9.18e-06	0.00387	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	9.15e-06	0.00385	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL10—multiple sclerosis	9.07e-06	0.00382	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	9.07e-06	0.00382	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL4—multiple sclerosis	8.83e-06	0.00372	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	8.63e-06	0.00363	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—FAS—multiple sclerosis	8.13e-06	0.00342	CbGpPWpGaD
Albendazole—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.11e-06	0.00342	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	8.09e-06	0.00341	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	8e-06	0.00337	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.35e-06	0.0031	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.35e-06	0.0031	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	7.31e-06	0.00308	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—BCHE—multiple sclerosis	7.27e-06	0.00306	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	7.15e-06	0.00301	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	7.14e-06	0.00301	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	7e-06	0.00295	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CD80—multiple sclerosis	6.75e-06	0.00284	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	6.66e-06	0.00281	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	6.66e-06	0.00281	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	6.56e-06	0.00276	CbGpPWpGaD
Albendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.38e-06	0.00269	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—POMC—multiple sclerosis	6.22e-06	0.00262	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—CCL2—multiple sclerosis	6.09e-06	0.00256	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	6.01e-06	0.00253	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	5.86e-06	0.00247	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.84e-06	0.00246	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	5.83e-06	0.00246	CbGpPWpGaD
Albendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	5.43e-06	0.00229	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	5.34e-06	0.00225	CbGpPWpGaD
Albendazole—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.17e-06	0.00218	CbGpPWpGaD
Albendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.92e-06	0.00207	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—MYC—multiple sclerosis	4.83e-06	0.00203	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.76e-06	0.002	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.74e-06	0.002	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	4.72e-06	0.00199	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.69e-06	0.00197	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.69e-06	0.00197	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.69e-06	0.00197	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—SRM—multiple sclerosis	4.65e-06	0.00196	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	4.56e-06	0.00192	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4.55e-06	0.00192	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	4.55e-06	0.00192	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	4.46e-06	0.00188	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—MYC—multiple sclerosis	4.32e-06	0.00182	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—POMC—multiple sclerosis	4.31e-06	0.00181	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	4.25e-06	0.00179	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	4.25e-06	0.00179	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—MAPK1—multiple sclerosis	4.22e-06	0.00178	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.01e-06	0.00169	CbGpPWpGaD
Albendazole—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.99e-06	0.00168	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.77e-06	0.00159	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—POMC—multiple sclerosis	3.76e-06	0.00158	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—SRM—multiple sclerosis	3.71e-06	0.00156	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.7e-06	0.00156	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—CCL2—multiple sclerosis	3.68e-06	0.00155	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.6e-06	0.00152	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3.45e-06	0.00145	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	3.28e-06	0.00138	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	3.28e-06	0.00138	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.2e-06	0.00135	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.18e-06	0.00134	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GPC5—multiple sclerosis	3e-06	0.00126	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—SRM—multiple sclerosis	2.96e-06	0.00125	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—MYC—multiple sclerosis	2.91e-06	0.00123	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	2.85e-06	0.0012	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.75e-06	0.00116	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.62e-06	0.0011	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.62e-06	0.0011	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MYC—multiple sclerosis	2.61e-06	0.0011	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MAPK1—multiple sclerosis	2.55e-06	0.00107	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—RRM1—multiple sclerosis	2.48e-06	0.00105	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GPC5—multiple sclerosis	2.39e-06	0.00101	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—SRM—multiple sclerosis	2.29e-06	0.000963	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.12e-06	0.000893	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	2.09e-06	0.000879	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	2.09e-06	0.000879	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.04e-06	0.00086	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—RRM1—multiple sclerosis	1.98e-06	0.000835	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.93e-06	0.000811	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.91e-06	0.000804	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.83e-06	0.00077	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.82e-06	0.000768	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.79e-06	0.000754	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.7e-06	0.000718	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.65e-06	0.000697	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.61e-06	0.000679	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.61e-06	0.000679	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.58e-06	0.000667	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.51e-06	0.000635	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.47e-06	0.000621	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—BCHE—multiple sclerosis	1.43e-06	0.0006	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.23e-06	0.000517	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.22e-06	0.000514	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.15e-06	0.000482	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—BCHE—multiple sclerosis	1.14e-06	0.00048	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.05e-06	0.000444	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.62e-07	0.000405	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—BCHE—multiple sclerosis	9.09e-07	0.000383	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—APOE—multiple sclerosis	8.58e-07	0.000361	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—POMC—multiple sclerosis	7.37e-07	0.00031	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.02e-07	0.000295	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—APOE—multiple sclerosis	6.85e-07	0.000288	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—ALB—multiple sclerosis	6.72e-07	0.000283	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—POMC—multiple sclerosis	5.89e-07	0.000248	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—APOE—multiple sclerosis	5.47e-07	0.00023	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—ALB—multiple sclerosis	5.37e-07	0.000226	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—POMC—multiple sclerosis	4.7e-07	0.000198	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—ALB—multiple sclerosis	4.28e-07	0.00018	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—APOE—multiple sclerosis	4.22e-07	0.000178	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—POMC—multiple sclerosis	3.63e-07	0.000153	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—ALB—multiple sclerosis	3.31e-07	0.000139	CbGpPWpGaD
